Inhaled Fluticasone Furoate for Ambulatory Treatment of COVID-19
Compared with placebo in ambulatory patients with confirmed COVID-19 who were aged 30 years or older, inhaled fluticasone furoate for 14 days did not shorten
Compared with placebo in ambulatory patients with confirmed COVID-19 who were aged 30 years or older, inhaled fluticasone furoate for 14 days did not shorten
The American College of Physicians (ACP) updates its living, rapid practice points focusing on 22 outpatient treatments for COVID-19 and provides a literature review to
Among immunocompromised patients hospitalized for COVID-19, “prompt initiation of remdesivir … is associated with significant survival benefit across all variant waves,” researchers report. “These findings
For the treatment of multisystem inflammatory syndrome in children (MIS-C), glucocorticoids and intravenous immunoglobulin (IVIG) decrease hospital length of stay (LOS) when given early in
In 2 studies of adults aged 50 years or older, bivalent mRNA booster vaccines with the original SARS-CoV-2 and omicron BA.4-5 or BA.1 subvariants were
Adults who received different primary and booster COVID-19 vaccines had better protection against severe, omicron-related COVID-19 outcomes compared with those receiving the same vaccines for
During the pandemic, the incidence of type 1 diabetes (T1D) increased, but the jump could not be attributed to COVID-19 in a 2015–2021 study of
Using data from the period of omicron dominance in England, the COVID-19 risk prediction algorithm QCOVID4 more accurately identified individuals at the highest levels of
For improving 30-day outcomes among U.S. veterans with COVID-19, ritonavir-boosted nirmatrelvir reduced both hospitalizations and mortality, while molnupiravir reduced mortality but not hospitalizations, researchers report.
Nearly one-fifth of unvaccinated people who contracted SARS-CoV-2 had post-COVID-19 symptoms up to 2 years after infection, a study shows. “Effective interventions are needed to